mRNA Therapeutics Platform Application
Not Specified
ResearchActive
Key Facts
About Lupagen
Lupagen is pioneering an extracorporeal bedside delivery platform aimed at transforming the administration of cell and gene therapies. Its Xynvivo™ System enables a simplified, potentially lower-cost process that can be applied to both ex vivo cell therapy and in vivo gene therapy programs, addressing critical industry pain points like high manufacturing costs, complex logistics, and safety concerns related to systemic vector administration. By offering a combination of proprietary technology and collaborative services from preclinical through commercial stages, Lupagen seeks to expand patient access and provide biopharma partners with a differentiated and accelerated path to market.
View full company profileTherapeutic Areas
Other Not Specified Drugs
| Drug | Company | Phase |
|---|---|---|
| FL116 | Forlong Biotechnology | Not specified |
| FL117 | Forlong Biotechnology | Not specified |
| FL118 | Forlong Biotechnology | Not specified |
| FL301 | Forlong Biotechnology | Not specified |
| JSKN016 | AlphaMab Oncology | Phase 1 |
| JSKN033 | AlphaMab Oncology | Phase 1 |
| JSKN022 | AlphaMab Oncology | Phase 1 |
| JSKN027 | AlphaMab Oncology | Phase 1 |
| KN019 | AlphaMab Oncology | Phase 1 |
| New TCM Formulations | China SXT Pharmaceuticals | Research / Pre-clinical |
| Long-acting Leronlimab | CytoDyn | Preclinical |
| SR2162 | SIMR (Australia) Biotech | IND Approved |